Target intelligence / Profile preview

Premature termination codon caused by Arg-to-TGA mutation in mRNA

Molecular classification
Other (genetic mutation, not a protein or receptor)
01

Overview

A premature termination codon (PTC) Arg-TGA in mRNA occurs when a point mutation converts a codon for arginine (such as CGA) to the stop codon TGA within a gene's coding sequence. This results in the early termination of translation, leading to truncated, usually nonfunctional, and sometimes toxic protein products. The truncated mRNA may also be rapidly degraded by the nonsense-mediated decay pathway. PTCs are significant contributors to severe genetic diseases, including cystic fibrosis, Duchenne muscular dystrophy, and many others. Therapeutically, small molecules and engineered tRNAs are being explored to enable readthrough of PTCs, restoring some full-length protein production.

Other names
Premature stop codon (Arg-to-TGA)Opal nonsense mutation at Arg codonNonsense codon (Arg to TGA)
02

Mechanism of action

Promoting translational readthrough of premature stop codons (e.g., by Ataluren or aminoglycosides)

03

Biological functions

Disruption of translationActivation of nonsense-mediated decay (NMD)Production of truncated protein
04

Disease associations

CancerNeurodegenerative diseaseMuscular dystrophyCystic fibrosisOther genetic diseases (accounts for 10–15% of severe inherited diseases)
05

Safety considerations

Off-target readthrough of normal stop codons by therapeutic agents, leading to faulty, extended proteinsToxicity/truncation effects of aberrant protein products
06

Interacting drugs

Ataluren (Translarna)

1 more in the full profile.

07

Biomarkers

Presence of specific PTC mutation (e.g., via gene sequencing)

Beyond the preview

Go deeper on Premature termination codon caused by Arg-to-TGA mutation in mRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Premature termination codon caused by Arg-to-TGA mutation in mRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call